Table 5 Clinical and pathological features and PPARγ expression in papillary carcinomas

From: Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours

 

PPARγ immunohistochemistry

 

PTC

All (n=39)

Negative (n=20)

Positive (n=19)

P-value

Age at diagnosis (years±s.d.)

41.0±19.9

38.7±18.7

43.5±21.3

NS

F/M ratio

2.5/1

1.9/1

3.4/1

NS

Tumour size (cm±s.d.)

3.7±2.4

3.9±2.1

3.5±2.3

NS

MACIS (mean±s.d.)

5.5±1.8

5.6±2.0

5.5±1.7

NS

Class a

   

NS

 I

20

11 (55%)

9 (45%)

 

 II

6

3 (50%)

3 (50%)

 

 III

9

2 (22%)

7 (78%)

 

 IV

3

3 (100%)

0

 

Predominant pattern

   

0.01

 Classic

18

5 (28%)

13 (72%)

 

 Follicular

15

12 (80%)

3 (20%)

 

 Others

6

3 (50%)

3(50%)

 

Poorly differentiated areas

6

4 (67%)

2 (33%)

NS

Local invasion

13

6 (46%)

7 (54%)

NS

Vascular invasion

9

4 (44%)

5 (56%)

NS

Clinical status a

   

NS

 Persistent

9

3 (33%)

6 (67%)

 

 Remission

29

16 (55%)

13 (45%)

 
  1. PPAR=peroxisome proliferator-activated receptor; PTC=papillary thyroid carcinoma; s.d.=standard deviation; NS=not significant.
  2. aLoss of follow-up of one patient.